ES2093776T3 - Metodo para producir cetolactonas alfa,beta-insaturadas. - Google Patents

Metodo para producir cetolactonas alfa,beta-insaturadas.

Info

Publication number
ES2093776T3
ES2093776T3 ES92302992T ES92302992T ES2093776T3 ES 2093776 T3 ES2093776 T3 ES 2093776T3 ES 92302992 T ES92302992 T ES 92302992T ES 92302992 T ES92302992 T ES 92302992T ES 2093776 T3 ES2093776 T3 ES 2093776T3
Authority
ES
Spain
Prior art keywords
beta
producing alpha
ketolactones
unsaturated
unsaturated ketolactones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92302992T
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Tomio Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of ES2093776T3 publication Critical patent/ES2093776T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES92302992T 1991-04-04 1992-04-03 Metodo para producir cetolactonas alfa,beta-insaturadas. Expired - Lifetime ES2093776T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7148391 1991-04-04

Publications (1)

Publication Number Publication Date
ES2093776T3 true ES2093776T3 (es) 1997-01-01

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92302992T Expired - Lifetime ES2093776T3 (es) 1991-04-04 1992-04-03 Metodo para producir cetolactonas alfa,beta-insaturadas.

Country Status (11)

Country Link
US (1) US5229529A (enExample)
EP (1) EP0507625B1 (enExample)
JP (1) JPH089608B2 (enExample)
KR (1) KR970003125B1 (enExample)
AT (1) ATE141921T1 (enExample)
CA (1) CA2064481C (enExample)
DE (1) DE69213067T2 (enExample)
DK (1) DK0507625T3 (enExample)
ES (1) ES2093776T3 (enExample)
GR (1) GR3020903T3 (enExample)
TW (1) TW197439B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0643051T3 (da) * 1992-09-30 2000-04-17 R Tech Ueno Ltd Fremgangsmåde til fremstilling af alfa,beta-umættede ketoner
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US20040234472A1 (en) * 2001-04-20 2004-11-25 Jackson John K. Micellar drug delivery systems for hydrophobic drugs
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
CA2637797C (en) * 2006-02-07 2015-03-17 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
US8168216B2 (en) 2006-03-22 2012-05-01 Medigene Ag Treatment of triple receptor negative breast cancer
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
IN2015DN00552A (enExample) 2012-07-19 2015-06-26 Redwood Bioscience Inc
CA2890190A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP3300745B9 (en) 2013-02-15 2020-04-15 The Regents of the University of California Chimeric antigen receptor and methods of use thereof
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
KR102319882B1 (ko) 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
JP6877049B2 (ja) 2015-09-25 2021-05-26 ゼットワイ セラピューティクス インク．Ｚｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
AU2017299374B2 (en) 2016-06-01 2021-05-27 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
SG11201906468TA (en) 2017-01-18 2019-08-27 F1 Oncology Inc Chimeric antigen receptors against axl or ror2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN111065623B9 (zh) 2017-05-24 2024-10-25 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2019195596A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
US12144826B2 (en) 2018-04-06 2024-11-19 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
CA3096838A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
US11529402B2 (en) 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP2022520220A (ja) 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
CA3131895A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
US20230002740A1 (en) 2019-12-12 2023-01-05 Ignite Immunotherapy, Inc Variant oncolytic vaccinia virus and methods of use thereof
MX2022009355A (es) 2020-01-29 2022-09-02 Kenjockety Biotechnology Inc Anticuerpo anti-mdr1 y uso del mismo.
US20230212305A1 (en) 2020-06-04 2023-07-06 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
CA3182969A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN116133671A (zh) 2020-07-14 2023-05-16 辉瑞公司 重组牛痘病毒
US20230272117A1 (en) 2020-09-02 2023-08-31 Kenjockety Biotechnology, Inc. Anti abcc1 antibodies and uses thereof
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
JP2023551203A (ja) 2020-11-20 2023-12-07 アール．ピー．シェーラー テクノロジーズ、エルエルシー 抗体－薬物コンジュゲートのためのグリコシド二重切断リンカー
CA3238353A1 (en) 2021-12-13 2023-06-22 William Robert ARATHOON Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (enExample) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
EP0219580B1 (en) * 1985-09-18 1989-11-29 The Upjohn Company Stereo-selective reduction
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center （２−クロロ−３−オキソ−１−アルケニル）−ビシクロ〔３．３．０〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
DE3888542T2 (de) * 1987-09-04 1994-07-21 Upjohn Co Verfahren zur herstellung von prostaglandinzwischenprodukten.

Also Published As

Publication number Publication date
CA2064481A1 (en) 1992-10-05
ATE141921T1 (de) 1996-09-15
DK0507625T3 (da) 1996-09-16
TW197439B (enExample) 1993-01-01
CA2064481C (en) 1996-12-24
KR920019771A (ko) 1992-11-20
JPH089608B2 (ja) 1996-01-31
EP0507625B1 (en) 1996-08-28
DE69213067D1 (de) 1996-10-02
DE69213067T2 (de) 1997-01-16
GR3020903T3 (en) 1996-11-30
US5229529A (en) 1993-07-20
JPH0592965A (ja) 1993-04-16
KR970003125B1 (ko) 1997-03-14
EP0507625A1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
ES2093776T3 (es) Metodo para producir cetolactonas alfa,beta-insaturadas.
ATE194601T1 (de) Verfahren zur herstellung von pyrimidinverbindungen
ES469394A1 (es) Un procedimiento para la preparacion de compuestos polieni- cos
MX17846A (es) Proceso para la preparacion de nuevos derivados de 9h purina.
MX158470A (es) Procedimiento para la produccion de metanol a partir de gas de sintesis
EP0165458A3 (en) (+)-ambrox, process for production thereof and use thereof
IT7819980A0 (it) Procedimento per la produzione di oggetti di carbonio o grafite con elevata solidita'.
ES2060354T3 (es) Procedimiento para la obtencion de esclareoluro.
NO922321D0 (no) Bis(fluormetyl)eter, fremgangsmaate for fremstilling, samtfremgangsmaate for fremstilling av difluormetan av bis(fluormetyl)eter
BR9200627A (pt) Processo para a preparacao de um composto e composto obtido
ES2057289T3 (es) Procedimiento para la obtencion de octadienoles.
ES2045215T3 (es) (+)-o (+)-1-(2-n-aminoetil sustituido) -1-metil-7-metoxi-1,2,3,4-tetrahidronaftaleno, y procedimiento para su produccion.
ES2177877T3 (es) Procedimiento para la fabricacion de 1,4-bis(aminometil)ciclohexano.
ES476420A1 (es) Procedimiento para la obtencion de un o-ftalaldehido, en ca-so dado sustituido.
ES2077781T3 (es) Procedimiento para la fabricacion de difosfanos solubles al agua.
DK0643051T3 (da) Fremgangsmåde til fremstilling af alfa,beta-umættede ketoner
ES536973A0 (es) Metodo de preparar dimetiloctenonas
ES2120098T3 (es) Procedimiento y productos intermedios para la preparacion de 5-oxaespiro(2.4)heptan-6-ona.
ES2118828T3 (es) Procedimiento para la obtencion de acidos 2,5-dihidroxifenilaceticos.
IT9047532A1 (it) Procedimento per la produzione di feltri per cappello.
BG43006A3 (en) Method for preparing condensed as- triazines
IL101052A (en) Process for producing glyceraldehyde- 3-pentanide
MX9205610A (es) Procedimiento para la preparacion de: acido (+ -)-2(6-metoxi-2-naftil)-propionico.
BG43004A3 (en) Method for preparing condensed as- triazines
AU549872B2 (en) 4-oxymethyl-5-acyl-1,3-dihydro-2h-imidazol-2-ones

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 507625

Country of ref document: ES